Epidemiology and Treatment of Mucormycosis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Mucormycosis is an uncommon but aggressive opportunistic fungal infection that afflicts patients with severe underlying immunosuppression, uncontrolled hyperglycemia and/or ketoacidosis, patients with iron overload resulting from frequent blood transfusions or blood disorders and occasionally healthy patients who are inoculated with fungal spores through traumatic injuries. The clinical presentation of mucormycosis is initially indistinguishable from other common infections, and if not diagnosed early and aggressively treated, it is almost always fatal. In this article we summarize recent changes in the epidemiology of mucormycosis, discuss diagnostic and clinical clues suggestive of the infection and provide a general strategy for managing the infection in the absence of data from well-controlled, prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Self-citationNovel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Self-citationRees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · cited 2×
“7 mucormycosis cases per 1 million people, or approximately 500 cases per year [30].”
Necrotizing Cutaneous Mucormycosis after a Tornado in Joplin, Missouri, in 2011
Neblett Fanfair, R., Benedict, K., Bos, J., Bennett, S. D., Lo, Y.-C., Adebanjo, T., Etienne, K., Deak, E., Derado, G., Shieh, W.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204781 · Cited by 360 · cited 1×
“For example, necrotizing soft tissue infections were reported in 13 patients who experienced blunt or penetrating trauma associated with the devastating Joplin tornado in 2011 [20].”
Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr375 · Cited by 308
Self-citationThe iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308 · cited 1×
“Specifically, administration of newer iron chelators without xenosiderophore properties (deferiprone and deferasirox) have actually shown protective effects in animal models of invasive mucormycosis [41,49,50].”
Cited by
Azole antifungals: 35 years of invasive fungal infection management
Allen, D., Wilson, D., Drew, R., & Perfect, J. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1032939 · Cited by 255
“Furthermore, rates of ‘difficult-to-treat’ molds, including formerly rare non-Aspergillus molds, with high-level resistance to most antifungals have also been on the rise [2,3].”
BackgroundCandida auris Genetics and Emergence
Chowdhary, A., Jain, K., & Chauhan, N. (2023) · Annual Review of Microbiology · doi:10.1146/annurev-micro-032521-015858 · Cited by 158
Koselny, K., Green, J., DiDone, L., Halterman, J. P., Fothergill, A. W., Wiederhold, N. P., Patterson, T. F., Cushion, M. T., Rappelye, C., Wellington, M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-16 · Cited by 83
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Bellanger, A.-P., Tatara, A. M., Shirazi, F., Gebremariam, T., Albert, N. D., Lewis, R. E., Ibrahim, A. S., & Kontoyiannis, D. P. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw090 · Cited by 41
Self-citationComparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris
Shivarathri, R., Jenull, S., Chauhan, M., Singh, A., Mazumdar, R., Chowdhary, A., Kuchler, K., & Chauhan, N. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02276-21 · Cited by 41
Metadata
- Authors
- Lewis, R. E., & Kontoyiannis, D. P.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2013-09
- Volume
- 8
- Issue
- 9
- Pages
- 1163-1175
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2061238584
- Cited by
- 128
- References
- 7
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.